Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of bexicaserin in developmental and epileptic encephalopathies
NL-OMON59486Phase 3Completed
- Sponsor
- Longboard Pharmaceuticals
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bexicaserin in epileptic encephalopathy and Lennox-Gastaut syndrome (LGS) (2 arms), sponsored by Longboard Pharmaceuticals. Primary endpoint: Frequency percent change in countable motor seizures during Maintenance compared to Baseline. Started Sep 2025; status: completed.
02
Drugs
bexicaserin
03
Conditions
epileptic encephalopathyLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NL-OMON59486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59486.